ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform. The first of these new ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...
ALAMEDA, Calif. & MENLO PARK, Calif.--BioTime, Inc. (NYSE MKT: BTX) announced today that its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"), has raised $12.5 million through the sale of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results